Fairvalue-Calculator Fairvalue-Calculator
EN DE

Mayne Pharma Group (MAYNF) Fair Value & Analysis

Healthcare · US · Market cap $134M

Price$1.65
Fair Value$4.45
Upside+169.7%
Quality95/100
Evidence: Medium Range $2.67 – $5.76

Fair value as of: Jun 25, 2026

Analysis

Mayne Pharma Group (MAYNF) currently trades at $1.65, while our model-based Fair Value estimate is $4.45 — implying the stock looks roughly 169.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third-party customers. It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Open the full interactive analysis →

Similar stocks

McKesson Corporation (M1CK34) -80% Cencora, Inc (C1CO34) -89% Cardinal Health, Inc (CAH) -36% Sigma Healthcare Limited (SIGGF) -73% Sitka Gold Corp (SIG) -59% Shanghai Pharmaceuticals Holding (601607) +183%

Frequently asked questions

Is Mayne Pharma Group (MAYNF) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $4.45 versus a price of $1.65 — about +170% (undervalued). Model-based estimate, not financial advice.
What is the fair value of MAYNF?
Our 21-model fair value for Mayne Pharma Group is $4.45 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.65.
What is the quality score of MAYNF?
Mayne Pharma Group has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.